Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMT3KB4)

Drug Name

Lobeline Drug Info

Synonyms

lobeline; Lobelin; Inflatine; Lobeline [INN]; Lobelinum [INN-Latin]; Lobelina [INN-Spanish]; EINECS 202-012-3; BRN 0091533; AC1LEL62; ZINC56446; Ethanone, 2-(6-(2-hydroxy-2-phenylethyl)-1-methyl-2-piperidinyl)-1-phenyl-, (2R-(2alpha,6alpha(S*)))-; LS-88107

Indication

Disease Entry	ICD 11	Status	REF
Substance use disorder	6C4Z	Phase 2	[1]

Cross-matching ID

PubChem CID: 101616
ChEBI ID: CHEMBL122270
CAS Number: CAS 90-69-7
TTD Drug ID: DMT3KB4
VARIDT Drug ID: DR01063

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Synaptic vesicle amine transporter (SLC18A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Deutetrabenazine	DMUPFLI	Huntington disease	8A01.10	Approved	[3]
Reserpine	DM6VM38	Hypertension	BA00-BA04	Approved	[4]
Tetrabenazine	DMYWQ0O	Huntington disease	8A01.10	Approved	[4]
Alseroxylon	DMB47TQ	Hypertension	BA00-BA04	Approved	[5]
Valbenazine Tosylate	DMQSA2V	Tardive dyskinesia	8A02.10	Approved	[3]
Alkavervir	DMB4HFI	High blood pressure	BA00	Approved	[3]
Ingrezza	DMVPLNC	Tardive dyskinesia	8A02.10	Phase 4	[6]
NBI-98854	DMVO1C0	Movement disorder	8A07-8A0Z	Phase 3	[7]
AV 133	DM0EQ9X	Alzheimer disease	8A20	Phase 3	[8]
SOM3355	DMKCBSM	Huntington disease	8A01.10	Phase 2	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Synaptic vesicle amine transporter (SLC18A2)	TTNZRI3	VMAT2_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo. J Neurochem. 2013 Oct;127(2):187-98.
2	Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse. Curr Top Med Chem. 2011;11(9):1103-27.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells. J Neurosci. 2009 Jul 1;29(26):8530-8.
5	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
6	VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine). Prog Med Chem. 2018;57(1):87-111.
7	NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord. 2015 Oct;30(12):1681-7.
8	Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET. PLoS One. 2013 Sep 30;8(9):e75952.
9	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)